OPTIMUM®
Life Reinsurance

“The strength of expertise”

Orforglipron: A Next-Generation Oral GLP-1 Agonist

White Paper – October 2025

Optimum Re Life Research and Development – Biometric Risk

Introduction

Orforglipron is a first-in-class, orally available, small-molecule non-peptide **GLP-1 receptor agonist** currently in Phase 3 trials, with an FDA approval target anticipated in 2026. Unlike peptide-based injectables such as semaglutide or tirzepatide, orforglipron delivers GLP-1 receptor activation through a convenient, once-daily pill, making it a potential breakthrough in diabetes and obesity management.

Layout

Introduction 2
Development History 3
Key Benefits 3
Clinical Actions and Efficacy 4
Safety Profile 4
Accessibility, Manufacturing, and Scalability 4
Patient Adherence and System-Level Impact 5
Conclusion 5
References 5

Development History

Between 2010 and 2018, **Chugai Pharmaceutical (Japan)** conducted pioneering research that led to the discovery of this novel compound. Initially named **OWL833**, the program was later licensed to **Eli Lilly**, already a leader in the GLP-1 field with Mounjaro and Zepbound. Lilly acquired development rights for $50 million and has since advanced orforglipron into late-stage clinical testing. Orforglipron is considered a small molecule at 883 grams/mol.-- it is approximately one fifth the size of the injectable GLP-1s (which are >4000 grams/mol.) and structurally less complex than the injectable peptide-based drugs.

Key Benefits

Oral Convenience: Orforglipron is taken once daily, with no fasting or post-dose dietary restrictions-- oral semaglutide (such as Rybelsus) requires fasting conditions and strict dosing requirements.

High Bioavailability: In healthy adults, orforglipron achieves an oral bioavailability of approximately 79%, which stands in stark contrast to the very low bioavailability of oral semaglutide at just 0.8%.
This high bioavailability, combined with a half-life ranging from 29 to 49 hours, supports reliable and consistent once-daily dosing.

Drug	Mean Oral Bioavailability (%)
Orforglipron	79
Semaglutide	0.8

Oral Bioavailability Comparison



https://www.perplexity.ai/search/graph-of-graph-of-bioavailabil-Yzs4zOedQ4WVhyAPxeVTXg * **

Metabolic Stability: Unlike peptide-based injectables, orforglipron's small, non-peptide structure resists enzymatic digestion, ensuring efficient absorption and high bioavailability.

GLP-1 Receptor Engagement: Orforglipron binds with high affinity to GLP-1 receptors in the pancreas, liver, brain, and peripheral tissues. It strongly mimics native GLP-1 signaling, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, reducing appetite via central nervous system activity, and exerting broad metabolic benefits.

Clinical Actions and Efficacy

Glycemic Control: Orforglipron reduced HbA1c by **1.2–1.5%** in the ACHIEVE-1 trial, with reductions of HbA1c by up to **2.2%** in ACHIEVE-3 trial.

Weight Reduction: In the ATTAIN-1 trial:

- 6 mg daily led to a **7.5% weight loss.**
- 12 mg daily reduced weight by **8.4%.**
- 36 mg daily achieved **11.2% weight loss**, with:
  - 54.6% of participants losing ≥ 10% of baseline weight.
  - 36% losing ≥15%.
  - 8.4% achieving ≥20% loss.
- Importantly, weight reduction appeared *progressive*, with plateaus not yet clearly reached.

Anti-Inflammatory Effects: High-sensitivity CRP reduction by >40% was achievable, reflecting systemic anti-inflammatory benefits not only from weight and glycemic improvements but possibly via direct cytokine and immune-cell modulation.

Additional Pleiotropic Effects: Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol were significantly improved with orforglipron as compared to placebo.

Safety Profile

Adverse events: Were similar to those of injectable GLP-1 agonists, primarily **mild-to-moderate gastrointestinal symptoms** (nausea, diarrhea). In the ATTAIN study:

- Treatment discontinuation occurred in **5.3–10.3%** of orforglipron patients.
- Placebo group discontinuation: **2.7%**.

Accessibility, Manufacturing, and Scalability

Manufacturing Advantages: As a small molecule, orforglipron avoids the costly, complex peptide synthesis required for injectables, making production significantly cheaper and more scalable.

Lilly Manufacturing Expansion: A $6.5 billion Lilly facility in Houston, Texas, is being built to support global-scale production of orforglipron and other oral small molecules.

Pricing Outlook: Final pricing awaits FDA approval, but costs are projected to be lower than injectable GLP-1s, improving access across healthcare systems.

Global Reach: Oral formulations simplify storage, transport, and distribution, reducing the bottlenecks that currently constrain injectable GLP-1 supply.

Patient Adherence and System-Level Impact

Oral Administration Advantages: The oral route removes major barriers associated with injections, potentially improving **long-term adherence** in broader patient populations. Large-scale adoption could reduce overall healthcare costs for diabetes and obesity by preventing complications, hospitalizations, and inflammatory comorbidities.

Conclusion

Orforglipron represents a potentially transformative advancement in GLP-1 therapy. With efficacy approaching that of injectable GLP-1s, meaningful reductions in HbA1c, weight, inflammation, and other risk factors were impressive. With a safety profile consistent with the GLP-1 class, it offers a **convenient, scalable, and cost-effective oral therapy.** While ultimate weight loss may prove somewhat less than injectable formulations, the drug's **accessibility, affordability, and ease of use** position it as a critical tool in addressing the global burdens of type 2 diabetes and obesity.

References

1. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. Published online September 16, 2025. doi:10.1056/NEJMoa2511774.
2. Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu W-S, Liu R, et al; for the ACHIEVE-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes.N Engl J Med. 2025;393(11):1065-1076. doi:10.1056/NEJMoa2505669
3. Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J, Banerjee H, Pirro V, Kazda C, Mather K. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025 Jun 6;24(1):240. doi: 10.1186/s12933-025-02781-x. PMID: 40481478; PMCID: PMC12142847.
4. Kawai T, Sun B, Yoshino H, Feng D, Suzuki Y, Fukazawa M, Nagao S, Wainscott DB, Showalter AD, Droz BA, Kobilka TS, Coghlan MP, Willard FS, Kawabe Y, Kobilka BK, Sloop KW. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29959-29967. doi: 10.1073/pnas.2014879117. Epub 2020 Nov 11. PMID: 33177239; PMCID: PMC7703558.
5. Jones B. The therapeutic potential of GLP-1 receptor biased agonism. Br J Pharmacol. 2022 Feb;179(4):492-510. doi: 10.1111/bph.15497. Epub 2021 May 20. PMID: 33880754; PMCID: PMC8820210.
6. Luna Ceron E, Reddy SD, Kattamuri L, Muvva DM, Chozet L, Bright T. Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review. J Brown Hosp Med. 2025 Apr 1;4(2):19-32. doi: 10.56305/001c.132255. PMID: 40191699; PMCID: PMC11966775.
7. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head

---

* Morse BL, Bhattachar S, Ma X, Coutant DE, Czeskis B, Nicoll C, Cassidy KC. Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clin Pharmacol Drug Dev. 2025 Sep 1. doi: 10.1002/cpdd.1594. Epub ahead of print. PMID: 40888509.

** Overgaard RV, Navarria A, Ingwersen SH, Bækdal TA, Kildemoes RJ. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clin Pharmacokinet. 2021 Oct;60(10):1335-1348. doi: 10.1007/s40262-021-01025-x. Epub 2021 May 10. PMID: 33969456; PMCID: PMC8505367.

OPTIMUM®
Life Reinsurance

“ The strength of expertise ”

Who we are?

Since 1987, our company has been serving the US life and health reinsurance marketplace. Throughout the years, Optimum Life Reinsurance has maintained steady growth and profitability, earning a solid reputation as a reinsurer that provides efficient and professional client service.

Our mission is to support clients of all sizes by providing expertise and solutions in addition to reinsurance capacity. Year after year, we continue to successfully expand our presence in the market through organic growth, block acquisitions, and personalized solutions tailored to increase market share for our clients.

Optimum Life Reinsurance is the reinsurer of choice for more than 160 life insurance companies in the US and Caribbean markets.

About Optimum Financial Group

Optimum Financial Group is dedicated to the financial security of its clients since 1969. Global and privately-owned, it is active in the sectors of actuarial consulting, global asset management, general insurance, information technology, life insurance, life reinsurance, and real estate. The Group has over 700 employees within diverse subsidiaries operating in 20 business places in Canada, the United States and in France. Its revenues are nearly 1.4 billion Canadian dollars, its assets under management in Canada, the United States and in France totalise 8.4 billion Canadian dollars and its total assets rise up to nearly 6 billion Canadian dollars.

OPTIMUM RE INSURANCE COMPANY

1345 River Bend Drive, Suite 100
Dallas, TX 75247, U.S.A.
+1 214 528-2020
+1 214 528-2777

www.optimumre.com
www.optimumre.com/linkedin